Perform baseline bloodwork to evaluate for hepatic function and injury (ALT, AST, and serum bilirubin [total and direct]) before initiating VEOZAH. Do not start VEOZAH if ALT or AST is ≥2x the ULN or total bilirubin is elevated (e.g., ≥2x the ULN) for the evaluating laboratory. VEOZAH can be started if baseline hepatic transaminase evaluation is <2x the ULN and total bilirubin is normal.1
Perform follow-up evaluations of hepatic transaminase concentration at 3 months, 6 months, and 9 months after initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing of the skin or eyes) suggest liver injury.1
ALT=alanine aminotransferase, AST=aspartate aminotransferase, ULN=upper limit of normal.